TR200200099T2 - Th2 farklılaşma inhibitörleri - Google Patents

Th2 farklılaşma inhibitörleri

Info

Publication number
TR200200099T2
TR200200099T2 TR2002/00099T TR200200099T TR200200099T2 TR 200200099 T2 TR200200099 T2 TR 200200099T2 TR 2002/00099 T TR2002/00099 T TR 2002/00099T TR 200200099 T TR200200099 T TR 200200099T TR 200200099 T2 TR200200099 T2 TR 200200099T2
Authority
TR
Turkey
Prior art keywords
optionally substituted
substituted lower
differentiation inhibitors
solvati
prodrug
Prior art date
Application number
TR2002/00099T
Other languages
English (en)
Inventor
Arimura Akinori
Kawada Kenji
Original Assignee
Shionogi &Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi &Co., Ltd. filed Critical Shionogi &Co., Ltd.
Publication of TR200200099T2 publication Critical patent/TR200200099T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
    • C07C251/58—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
    • C07C211/49—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring having at least two amino groups bound to the carbon skeleton
    • C07C211/50—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring having at least two amino groups bound to the carbon skeleton with at least two amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Bu bulus, A, B ve C halkalarinin her birinin bir aromatik karbosiklik halka, bir heterosiklik halka vb; X' in tekil bir bag, -O-, -CH2-, _NH-, -SO- vb; Y' nin hidrojen, tercihe göre ikameli düsük degerli alkil, tercihe göre ikameli düsük degerli alkenil vb; V1 ve V2' nin her birinin bir tekil bag, -O-, -NH-, -O CH2- vb oldugu bir formül (I): ile temsil edilen bir bilesik, Th2 farklilasma inhibitörü olarak kullanilacak bir farmasötik terkip, bunun bir ön ilaci, farmasötik olarak kabul edilebilir tuzu veya solvati.
TR2002/00099T 1999-07-23 2000-07-14 Th2 farklılaşma inhibitörleri TR200200099T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20929899 1999-07-23

Publications (1)

Publication Number Publication Date
TR200200099T2 true TR200200099T2 (tr) 2002-06-21

Family

ID=16570644

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00099T TR200200099T2 (tr) 1999-07-23 2000-07-14 Th2 farklılaşma inhibitörleri

Country Status (16)

Country Link
US (1) US7008954B1 (tr)
EP (1) EP1206935A4 (tr)
KR (1) KR20020012309A (tr)
CN (1) CN1364080A (tr)
AU (1) AU763976B2 (tr)
BR (1) BR0012697A (tr)
CA (1) CA2375982A1 (tr)
HK (1) HK1046645A1 (tr)
HU (1) HUP0203575A3 (tr)
MX (1) MXPA01013452A (tr)
NO (1) NO20016401L (tr)
PL (1) PL353476A1 (tr)
RU (1) RU2230551C2 (tr)
TR (1) TR200200099T2 (tr)
WO (1) WO2001007032A1 (tr)
ZA (1) ZA200109785B (tr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020063837A (ko) * 1999-07-19 2002-08-05 시오노기세이야쿠가부시키가이샤 아실옥시메톡시카르보닐 측쇄를 갖는 삼환 화합물
US20040087620A1 (en) * 2001-01-18 2004-05-06 Tatsuo Tsuri Terphenyl compounds bearing substituted amino groups
JPWO2002057237A1 (ja) * 2001-01-22 2004-05-20 塩野義製薬株式会社 置換アミノ基を有するヘテロ３環化合物
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
JPWO2003030905A1 (ja) * 2001-10-01 2005-01-20 塩野義製薬株式会社 ジヒドロオロテートデヒドロゲナーゼ阻害剤
JP2005531574A (ja) 2002-05-22 2005-10-20 アムジエン・インコーポレーテツド 痛みの治療にバニロイド受容体リガンドとして使用するためのアミノ−ピリジン、−ピリジンおよびピリダジン誘導体
TW200410945A (en) 2002-08-08 2004-07-01 Amgen Inc Vanilloid receptor ligands and their use in treatments"
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
JP2007522233A (ja) 2004-02-11 2007-08-09 アムジエン・インコーポレーテツド バニロイド受容体リガンド及び治療におけるそれらの使用
MY139645A (en) 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
AU2005231507B2 (en) 2004-04-08 2012-03-01 Targegen, Inc. Benzotriazine inhibitors of kinases
NZ588896A (en) 2004-08-25 2012-05-25 Targegen Inc Heterocyclic compounds and methods of use
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
US7301022B2 (en) 2005-02-15 2007-11-27 Amgen Inc. Vanilloid receptor ligands and their use in treatments
JP2006298775A (ja) * 2005-04-15 2006-11-02 Dainippon Sumitomo Pharma Co Ltd 選択的Ｔｈ２免疫反応抑制剤
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
JP5408660B2 (ja) * 2007-09-04 2014-02-05 学校法人東京農業大学 パラテルフェニル化合物、その薬理学的に許容される塩、その製造方法及び用途
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EP2509961B1 (en) 2009-12-11 2016-03-09 Autifony Therapeutics Limited Imidazolidinedione derivatives
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
KR101862375B1 (ko) 2010-12-06 2018-05-29 오티포니 세라피틱스 리미티드 Kv3 억제제로서 유용한 하이단토인 유도체
US9193704B2 (en) 2011-06-07 2015-11-24 Autifony Therapeutics Limited Hydantoin derivatives as KV3 inhibitors
JP2015517563A (ja) 2012-05-22 2015-06-22 アウトイフオンイ トヘラペウトイクス リミテッド Ｋｖ３阻害剤としてのヒダントイン誘導体
CN104334547B (zh) 2012-05-22 2017-06-06 奥蒂福尼疗法有限公司 作为kv3抑制剂的三唑类
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA932233B (en) * 1992-03-27 1994-09-29 Peptide Technology Ltd Peptide T and related peptides in the treatment of inflammation including multiple sclerosis
US5693611A (en) * 1996-02-01 1997-12-02 Eli Lilly And Company Cyclic peptide antifungal agents
CN1101373C (zh) 1996-04-22 2003-02-12 盐野义制药株式会社 新三联苯化合物以及含有新三联苯化合物的药物
RU2200730C2 (ru) * 1996-07-31 2003-03-20 Шионоги Энд Ко., Лтд. Пара-терфенильные соединения, способ их получения (варианты) и фармацевтическая композиция (варианты)
HN1997000027A (es) * 1996-12-06 1997-06-05 Pfizer Prod Inc Derivados de 6-fenil piridil - 2 amina
AU7553198A (en) * 1997-06-12 1998-12-30 Sumitomo Pharmaceuticals Company, Limited Pyrazole derivatives
US6003360A (en) 1997-07-01 1999-12-21 Wilson Tool International, Inc. Press brake tool holder
PL341984A1 (en) * 1998-01-28 2001-05-07 Shionogi & Co Novel tricycle compounds
KR20020063837A (ko) * 1999-07-19 2002-08-05 시오노기세이야쿠가부시키가이샤 아실옥시메톡시카르보닐 측쇄를 갖는 삼환 화합물

Also Published As

Publication number Publication date
WO2001007032A1 (en) 2001-02-01
CN1364080A (zh) 2002-08-14
KR20020012309A (ko) 2002-02-15
AU6015900A (en) 2001-02-13
EP1206935A4 (en) 2008-07-30
MXPA01013452A (es) 2002-07-02
RU2230551C2 (ru) 2004-06-20
NO20016401L (no) 2002-01-23
CA2375982A1 (en) 2001-02-01
BR0012697A (pt) 2002-04-09
PL353476A1 (en) 2003-11-17
AU763976B2 (en) 2003-08-07
HK1046645A1 (zh) 2003-01-24
HUP0203575A2 (hu) 2003-02-28
US7008954B1 (en) 2006-03-07
NO20016401D0 (no) 2001-12-21
EP1206935A1 (en) 2002-05-22
HUP0203575A3 (en) 2003-11-28
ZA200109785B (en) 2002-11-28

Similar Documents

Publication Publication Date Title
DK1161428T3 (da) Pyrimidinforbindelser
AP2001002241A0 (en) Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents.
DE69710319D1 (de) Para-substituierte phenylpropansäure derivate als integrin-antagonisten
TR200103335T2 (tr) Proteaz inhibitörleri olarak amin türevleri
DE69811329D1 (de) Imidazolidin-4-on Derivate verwendbar als Antikrebsmittel
HUP0301573A2 (hu) Szubsztituált arilpirazinok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP9802859A2 (hu) Acil-amino-szalicilsav-amid-származékok és alkalmazásuk peszticidként
TR200200701T2 (tr) Altı-elementli aromatik nitrojenli halka bileşimleri.
DE60140456D1 (de) Aza heterocyclische derivate und ihre therapeutische verwendung
EP0638567A4 (en) ADENOSINE INHIBITORS.
TR200103183T2 (tr) Amin türevi bileşimler
NO20060219L (no) Forbindelser
HUP0203575A2 (hu) Th2 differenciálódás inhibitorokat tartalmazó gyógyszerkészítmények és alkalmazásuk
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
TR200400857T4 (tr) Yeni galantamın türevleri ve analogları
TR199902848T2 (tr) Ergolin türevleri ve bunlarin somatostatin reseptör antagonist olarak kullanimlari
DK1189900T3 (da) Heterocykliske aminopyrrolidinderivater som melatonerge lægemidler
TR200200125T2 (tr) Yeni aminotiyazol türevleri, bunların hazırlanması ve bunları içeren farmasötik kompozisyonlar.
HUP9701080A2 (hu) Virusellenes hatású vegyületet és hidroximsavszármazékot tartalmazó gyógyszerkészítmény
TW200510320A (en) Aminoquinoline derivatives and their use as adenosine A3 ligands
MX164198B (es) Una composicion farmaceutica
DE60039631D1 (de) Cyclopentyl sulfonamid derivaten
TR200400611T4 (tr) Sitalopramın preparasyon metodu
HUP9904594A2 (hu) Piperazinoszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE348800T1 (de) 4&#39;-methansulfonylbiphenylderivate als hochselektive cyclooxygenase-2-inhibitoren